Androgen receptor
Showing 26 - 50 of 8,225
PCOS, Polycystic Ovary Syndrome Trial in Charlottesville (Micronized progesterone, Placebo, Flutamide)
Recruiting
- PCOS
- Polycystic Ovary Syndrome
- Micronized progesterone
- +3 more
-
Charlottesville, VirginiaUniversity of Virginia
May 16, 2022
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer Trial
Not yet recruiting
- Hormone Receptor-positive Breast Cancer
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Oct 5, 2022
Metastatic Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Trial in United States (Darolutamide, Enzalutamide)
Recruiting
- Metastatic Prostate Cancer
- +3 more
-
San Diego, California
- +11 more
Nov 28, 2022
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in United States (Biomarker Analysis,
Active, not recruiting
- Estrogen Receptor Negative
- +6 more
- Biomarker Analysis
- +3 more
-
Birmingham, Alabama
- +8 more
Feb 3, 2022
Breast Cancer, Metastasis Trial in New York (Abemaciclib, Bicalutamide)
Recruiting
- Breast Cancer
- Metastasis
-
New York, New York
- +2 more
Oct 14, 2021
Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube Trial in United States (Enzalutamide)
Completed
- Advanced Epithelial Ovarian
- +3 more
-
Basking Ridge, New Jersey
- +5 more
Mar 4, 2022
Prostate Cancer, Stereotactic Body Radiation Therapy Trial (SBRT, STANDARD OF CARE)
Not yet recruiting
- Prostate Cancer
- Stereotactic Body Radiation Therapy
- SBRT
- STANDARD OF CARE
- (no location specified)
Jan 25, 2022
Metastatic Castration-resistant Prostate Cancer Trial (ONC-392, lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV
Not yet recruiting
- Metastatic Castration-resistant Prostate Cancer
- ONC-392
- lutetium Lu 177 vipivotide tetraxetan 7.4 GBq (200 mCi), IV infusion, Q6W for up to 6 doses.
- (no location specified)
Dec 27, 2022
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty Trial in Charlottesville (Micronized progesterone, Spironolactone, Placebo)
Recruiting
- Hyperandrogenism
- +2 more
- Micronized progesterone
- +2 more
-
Charlottesville, VirginiaUniversity of Virginia Clinical Research Unit
May 16, 2022
Prostate Cancer, Prostate Adenocarcinoma Trial (drug, other, procedure)
Not yet recruiting
- Prostate Cancer
- Prostate Adenocarcinoma
- Relacorilant
- +4 more
- (no location specified)
Feb 2, 2023
In-vitro Diagnostic Test to Predict COVID-19 Mortality and
Recruiting
- SARS-CoV 2
- +5 more
- CAG length <22
- CAG length >=22
-
Madrid, SpainHospital Universitario Ramon y Cajal
Feb 17, 2022
Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)
Recruiting
- Metastatic Hormone-sensitive Prostate Cancer
- Darolutamide (BAY1841788, Nubeqa)
- ADT
-
Homewood, Alabama
- +11 more
Jan 13, 2023
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on
Terminated
- Castration-Resistant Prostate Carcinoma
- +4 more
- Computed Tomography
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Sep 19, 2022
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial
Not yet recruiting
- Locally Advanced Salivary Gland Carcinoma
- +3 more
- Biopsy
- +3 more
- (no location specified)
Jan 10, 2023
Solid Tumor, Androgen Receptor Gene Overexpression Trial in Darlinghurst (SEVI-D (Seviteronel in combination with dexamthasone))
Terminated
- Solid Tumor
- Androgen Receptor Gene Overexpression
- SEVI-D (Seviteronel in combination with dexamthasone)
-
Darlinghurst, New South Wales, AustraliaSt Vincent's Hospital
Mar 2, 2021
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7 Trial in Houston (procedure, drug,
Recruiting
- Invasive Breast Carcinoma
- +11 more
- Axillary Lymph Node Dissection
- +5 more
-
Houston, Texas
- +1 more
Mar 10, 2022
Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen
Recruiting
- Castration-Resistant Prostate Carcinoma
- +7 more
- Biopsy
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2022
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma Trial in San Francisco (Apalutamide, Cetrelimab)
Recruiting
- Small Cell Neuroendocrine Carcinoma
- +2 more
- Apalutamide
- Cetrelimab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 21, 2022
Advanced Prostate Cancer Trial in Baltimore (Pelvic DCFPyL PET-MRI fusion or PET/MRI)
Recruiting
- Advanced Prostate Cancer
- Pelvic DCFPyL PET-MRI fusion or PET/MRI
-
Baltimore, MarylandThe Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mar 22, 2022
Triple Negative Breast Cancer Trial (Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel)
Not yet recruiting
- Triple Negative Breast Cancer
- Seviteronel-D (Seivteronel in combination with dexamethasone)
- Docetaxel
- (no location specified)
Sep 21, 2021
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer Trial in United States (VERU-111,
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Androgen Resistant Prostatic Cancer
- VERU-111
- Enzalutamide, Abiraterone
-
Anchorage, Alaska
- +43 more
Jan 3, 2023